Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting16-11-2021
16-11-2021
Biocon starts campaign to treat diabetic children, train healthcare workers
India has one of the largest populations of children and adolescents living with Type 1 diabetes in the world with an estimated 1 million patients in this age group15-11-2021
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day15-11-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Revised Intimation on Investor Meeting held on November 10, 202111-11-2021
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting11-11-2021
Covid reinforced global dependence on Indian IT sector: Kris Gopalakrishnan
Bengaluru Tech Summit 2021 unveiled by Gopalakrishnan, Biocon's Kiran Mazumdar Shaw, to be held during November 17-1909-11-2021
Biocon Ltd - 532523 - Biocon Biologics And Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee(r) (Insulin Glargine-Yfgn) Injection And Insulin Glargine (Insulin Glargine-Yfgn) Injection On Its National Formularies
Biocon Biologics and Viatris Announce Prime Therapeutics Prefers First-Ever Interchangeable Insulin Biosimilar Semglee(r) (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection on its National Formularies04-11-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting03-11-2021
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation - Q2 FY-22.02-11-2021
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting28-10-2021